A Lactobacillus reuteri vesicle gynecological gel for reshaping vaginal microenvironment and optimizing flora structure, and preparation method and application thereof

Through the use of Lactobacillus reuteri vesicle gynecological gel agent, the characteristics of selective bactericidal and collaborative repair of vaginal microecology have been solved in the prior art vaginitis treatment effect and pathogenic resistance of pathogenic bacteria in the prior art , effectively killing Staphylococcus aureus and Candida albicans and balance vaginal microecology.

CN118615324BActive Publication Date: 2024-11-15WEIFANG MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411090311.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-09
Publication Date
2024-11-15
Estimated Expiration
2044-08-09

AI Technical Summary

Technical Problem

The existing treatment methods for vaginitis cannot effectively kill pathogenic bacteria hidden in vaginal folds and cervical fornix, resulting in limited treatment effects. Commonly used disinfectant gels have a resistance to bacteria, increasing the difficulty of treatment.

Method used

Use Lactobacillus reuteri vesicles gynecological gel agent, which contains α-revoctosin, Centella asiaticin, serpin, Lactobacillus reuteri vesicles, inulin, carbomer 940, glycerol and ethylparaben, through selective bactericidal without inhibiting the beneficial bacteria in the vagina, reshape the vaginal microenvironment and optimize the bacterial structure.

Benefits of technology

This gel agent has a significant bactericidal effect on Staphylococcus aureus and Candida albicans at therapeutic doses, maintains vaginal microecology balance, has small side effects, is high in safety, and can effectively improve gynecological vaginal inflammation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118615324B_ABST
    Figure CN118615324B_ABST
Patent Text Reader

Abstract

The invention discloses a Lactobacillus reuteri vesicle gynecological gel for remodeling vaginal microenvironment and optimizing flora structure and its preparation method and application, and belongs to the field of medical technology. The Lactobacillus reuteri vesicle gynecological gel provided by the present invention includes α-mangostin, asiaticoside, osthole, Lactobacillus reuteri vesicle, inulin, carbomer 940, glycerol, triethanolamine, ethylparaben and sterile deionized water. The Lactobacillus reuteri vesicle gynecological gel prepared by the present invention is crystal clear, with suitable viscosity and good stability, and the Lactobacillus reuteri vesicle plays a role in participating in signal transduction and intercellular communication between bacteria and host, and can also inhibit the growth and colonization of pathogenic bacteria. The present invention proves that the Lactobacillus reuteri vesicle gynecological gel in the present invention has a good therapeutic effect on vaginitis through pharmacodynamic experiments, and has good market application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical technology, and specifically relates to a Lactobacillus reuteri vesicle gynecological gel for reshaping vaginal microenvironment and optimizing flora structure, and a preparation method and application thereof. Background Art

[0002] Vaginitis is a common and frequently occurring disease in women. In addition to causing discomfort in the vulva and vagina, it can also lead to a series of serious complications related to reproductive health, endangering women's reproductive health. Common vaginitis includes bacterial vaginosis, aerobic vaginal and vulvovaginal candidiasis and other gynecological inflammations. The main manifestations of vaginitis are vulvar itching, changes in the characteristics of leucorrhea to a certain extent, and different burning sensations in the vulva. The occurrence of vaginitis will cause patients to have obvious itching, which will continue to appear and affect their personal lives. If vaginitis is not treated for a long time, it will also lead to the continuous spread of inflammation, making it more likely to develop cervical erosion or cervicitis. If pathogens continue to enter the uterine cavity, it will cause fallopian tube and ovarian inflammation, pelvic inflammatory disease, etc. Studies have shown that in women of childbearing age, vaginitis can have a significant adverse effect on pregnancy, including chorioamnionitis, premature rupture of membranes, premature birth, neonatal infection and other adverse pregnancy outcomes.

[0003] Traditional treatments for vaginitis mainly include washing solutions or oral medications, as well as specialized disinfection gel products. However, a large number of pathogenic bacteria hide in the folds of the vagina and the cervical vault. External washing or medication cannot kill the pathogenic bacteria hidden in the folds and vaults. Some residual bacteria will continue to grow and multiply in the vagina. Oral medications cannot directly act on the affected area, resulting in limited effectiveness. Specialized disinfection gel products cannot selectively kill bacteria and are highly destructive, causing bacteria to develop drug resistance, thereby aggravating the condition and bringing more difficulties to treatment. Summary of the invention

[0004] In order to overcome the above-mentioned defects of the prior art, the purpose of the present invention is to provide a Lactobacillus reuteri vesicle gynecological gel for reshaping the vaginal microenvironment and optimizing the flora structure, as well as a preparation method and application thereof. The production process of the invention is simple and controllable, and it has an excellent bactericidal effect on Staphylococcus aureus and Candida albicans. At a therapeutic dose, it will not have an inhibitory effect on beneficial vaginal bacteria, and can effectively treat and improve gynecological vaginal inflammation, with few side effects and high safety.

[0005] In order to achieve the above-mentioned invention object, the present invention adopts the following technical solutions:

[0006] The invention provides a lactobacillus reuteri vesicle gynecological gel for reshaping vaginal microenvironment and optimizing flora structure. The gynecological gel comprises the following components: 0.0001%-10% of alpha-mangostin, 0.0001%-10% of asiaticoside, 0.0001%-10% of osthole, 0.0001%-10% of lactobacillus reuteri vesicle, 0.0001%-10% of inulin, 0.05%-5% of carbomer 940, 10%-30% of glycerol, 0.01%-0.5% of ethylparaben, triethanolamine for adjusting pH value to 5-12, and the balance being sterile deionized water.

[0007] Furthermore, the weight percentages of the components of the gynecological gel are as follows: 0.0001%-1% of α-mangostin, 0.0001%-1% of asiatica glycoside, 0.0001%-1% of osthole, 0.0001%-1% of Lactobacillus reuteri vesicles, 0.0001%-2% of inulin, 0.05%-5% of carbomer 940, 10%-30% of glycerol, 0.01%-0.5% of ethylparaben, triethanolamine for adjusting the pH to 5-12, and the balance being sterile deionized water.

[0008] Furthermore, the components of the gel are prepared according to the following weight ratios: 0.0001%-0.0025% of alpha-mangostin, 0.001%-0.1% of asiatica glycoside, 0.001%-0.1% of osthole, 0.0001%-0.1% of Lactobacillus reuteri vesicles, 0.01%-1% of inulin, 1% of carbomer 940, 20% of glycerol, 0.1% of ethylparaben, triethanolamine for adjusting the pH to 6.5, and the balance being sterile deionized water.

[0009] Furthermore, the components of the gel are prepared according to the following weight ratios: 0.0025% of alpha-mangostin, 0.05% of asiatica glycoside, 0.05% of osthole, 0.01% of Lactobacillus reuteri vesicles, 0.1% of inulin, 1% of carbomer 940, 20% of glycerol, 0.1% of ethylparaben, triethanolamine for adjusting pH to 6.5, and the balance is sterile deionized water.

[0010] The present invention also provides a method for preparing the Lactobacillus reuteri vesicle gynecological gel for reshaping the vaginal microenvironment and optimizing the flora structure, and the preparation method comprises the following steps:

[0011] (1) First, α-mangostin and osthole are dissolved in an organic solvent respectively, and then sterile deionized water is added to dilute them into α-mangostin solution and osthole solution; then, a required amount of asiatica glycoside, Lactobacillus reuteri vesicles, inulin and ethylparaben are added to obtain a mixed active ingredient;

[0012] (2) Add carbomer 940 to sterile deionized water and glycerol while stirring; stir until carbomer 940 is fully swollen, and let stand overnight to eliminate bubbles; adjust the pH to 6-7 with triethanolamine, and add sterile deionized water to form a gel matrix;

[0013] (3) Adding the mixed medicinal components into the gel matrix and stirring evenly to obtain the Lactobacillus reuteri vesicle gynecological gel.

[0014] Furthermore, the organic solvent in step (1) is at least one of methanol, anhydrous ethanol, isopropanol or acetone.

[0015] Furthermore, the volume ratio concentration of the organic solvent in step (1) is 0.5% to 0.8%.

[0016] Furthermore, the preparation method of the Lactobacillus reuteri vesicles is as follows: Lactobacillus reuteri is aseptically inoculated into a culture medium for cultivation, the culture fluid after cultivation is centrifuged, the supernatant is filtered through a 0.22 μm filter membrane, the filtrate is concentrated using an 80 kDa~120 kDa concentrator, and the vesicles are obtained by centrifugation.

[0017] The present invention also provides application of the Lactobacillus reuteri vesicle gynecological gel in preparing medicine for treating and improving gynecological vaginal inflammation.

[0018] The present invention also provides the use of the Lactobacillus reuteri vesicle gynecological gel in preparing medicines for reshaping vaginal microenvironment and optimizing flora structure.

[0019] Furthermore, the Lactobacillus reuteri vesicle gynecological gel can effectively kill Staphylococcus aureus and Candida albicans.

[0020] Furthermore, the dosage concentration range of α-mangostin in the drug is 0.39 μg / ml~100 μg / ml.

[0021] The advantages and beneficial technical effects of the present invention are: the Lactobacillus reuteri vesicle gynecological gel loaded with multiple natural active ingredients provided by the present invention has a selective bactericidal effect without inhibiting Lactobacillus reuteri, and can maintain the balance of vaginal microecology; multiple Chinese medicine ingredients are used to synergistically sterilize while stably repairing the vaginal microecological environment. The Lactobacillus reuteri vesicle has membrane proteins and signal molecules on its surface, and contains various enzymes, bacteriocins, nucleic acids, lipids and other functional proteins inside, which can help inhibit other bacteria.

[0022] The main functions include: (1) Lactobacillus reuteri vesicles prevent pathogenic bacteria from attaching by supporting the colonization of beneficial bacteria. (2) Lactobacillus reuteri vesicles can deliver bacteriocin peptides to pathogenic bacteria, inhibiting their growth, but allowing their own proliferation. (3) Lactobacillus reuteri vesicles can carry their bacterial active ingredients through the mucus layer to interact with host immune cells. Inulin can promote the recovery of the acidic microenvironment and promote the proliferation of vaginal probiotics. It can be used to balance the microenvironment of vaginal diseases, balance the flora, and promote late repair. Through the evaluation of the therapeutic effect of vaginitis in rats, Lactobacillus reuteri vesicle gynecological gel loaded with multiple natural active ingredients has a very good therapeutic effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 This is the result diagram of the bactericidal effect of α-mangostin on Staphylococcus aureus;

[0024] Figure 2 This is a graph showing the antibacterial and bactericidal effects of gynecological gels with different α-mangostin concentrations on Staphylococcus aureus;

[0025] Figure 3 This is a graph showing the bactericidal effect of α-mangostin on Lactobacillus crispatus;

[0026] Figure 4 This is a diagram showing the results of the biocompatibility evaluation of α-mangostin on human immortalized epidermal cells;

[0027] Figure 5 This is a schematic diagram of establishing a rat vaginitis animal model;

[0028] Figure 6 The results of culturing samples on solid culture medium after rats were modeled with Staphylococcus aureus without treatment (left picture) and after seven days of gel treatment (right picture);

[0029] Figure 7 The results of culturing rat samples on solid culture medium without treatment (left picture) and after seven days of gel treatment (right picture) after Candida albicans modeling;

[0030] Figure 8 These are the vaginal tissue pathology test results of rats without treatment after modeling with Staphylococcus aureus and Candida albicans (left picture is 10×, right picture is 20×);

[0031] Fig. 9 These are the results of vaginal tissue pathology in rats treated with gel after modeling with Staphylococcus aureus and Candida albicans (left picture is 10×, right picture is 20×). DETAILED DESCRIPTION

[0032] In order to understand the purpose and application of the present invention in more detail, the following specific examples are provided for further detailed description.

[0033] The Lactobacillus reuteri vesicle gynecological gel provided by the present invention for reshaping the vaginal microenvironment and optimizing the flora structure includes effective ingredients α-mangostin (AMG), asiaticoside, osthole, Lactobacillus reuteri vesicles (EVs), inulin, carbomer 940, glycerol, triethanolamine, ethylparaben and sterile deionized water. α-mangostin, asiaticoside, osthole, Lactobacillus reuteri vesicles are medicinal ingredients, inulin is a prebiotic, carbomer 940 is a thickener, glycerol is a moisturizer, ethylparaben is a preservative, and triethanolamine is a pH regulator.

[0034] Example 1: Solubility experiment of α-mangostin and osthole in organic solvents

[0035] Take 0.6 mg of α-mangostin (AMG) in a 2 ml centrifuge tube, add 10 μl of anhydrous ethanol to dissolve AMG, add water to 2 ml, AMG does not precipitate, at this time the concentration of anhydrous ethanol is 0.5%, and the cytotoxic concentration of ethanol is 1% and above after investigation, therefore, α-mangostin in the present invention is dissolved with 0.5% ethanol. The dissolution method of osthole is the same as that of α-mangostin.

[0036] The experimental results are shown in Table 1. The α-mangostin and osthole in the Lactobacillus reuteri vesicle gynecological gel for reshaping the vaginal microenvironment and optimizing the flora structure prepared by the present invention have good solubility in methanol, anhydrous ethanol, isopropanol or acetone, and are insoluble in dilute alkaline solution, Tween 20 and Tween 80. Therefore, in view of the problem of poor water solubility of α-mangostin and osthole, they can be dissolved in methanol, anhydrous ethanol, isopropanol or acetone and then diluted with water to the required concentration to obtain a uniform and stable solution.

[0037] Table 1 Solubility of α-mangostin and osthole in some organic solvents

[0038]

[0039] Example 2: Extraction and separation of Lactobacillus reuteri vesicles in the Lactobacillus reuteri vesicle gynecological gel

[0040] The extraction and separation of the Lactobacillus reuteri vesicles used in the Lactobacillus reuteri vesicle gynecological gel of the present invention comprises the following steps:

[0041] (1) Lactobacillus reuteri (commercially available) was inoculated into a 250 mL conical flask using aseptic operation and cultured at room temperature of 37°C overnight;

[0042] (2) The Lactobacillus reuteri culture solution was centrifuged at 10,000 × g for 30 min at 4°C, and the supernatant was filtered through a 0.22 μm filter membrane to remove large particles such as bacteria;

[0043] (3) The filtrate was concentrated using a 100 kDa concentrator. The concentrate was ultracentrifuged at 200,000 × g for 2 h at 4°C.

[0044] (4) Wash three times with PBS, resuspend the obtained vesicle pellet in sterile phosphate buffered saline (PBS), and store in a -80°C refrigerator until ready for use.

[0045] Example 3: Preparation method of the Lactobacillus reuteri vesicle gynecological gel

[0046] The Lactobacillus reuteri vesicle gynecological gel for reshaping the vaginal microenvironment and optimizing the flora structure provided by the present invention is prepared through optimization from the following raw materials in percentage by weight: 0.0025% of alpha-mangostin, 0.05% of asiatica glycoside, 0.05% of osthole, 0.01% of Lactobacillus reuteri vesicle, 0.1% of inulin, 1% of carbomer 940, 20% of glycerol, 0.1% of ethylparaben, triethanolamine for adjusting the pH to 6.5, and the balance being sterile deionized water.

[0047] The preparation method of the Lactobacillus reuteri vesicle gynecological gel of the present invention specifically comprises the following steps:

[0048] (1) First, α-mangostin and osthole are dissolved in anhydrous ethanol, and sterile deionized water is added to dilute them into 50 ml of 0.005% α-mangostin and 0.1% osthole stock solutions, and then the required amounts of asiatica glycoside, Lactobacillus reuteri vesicles, inulin and ethylparaben are added to make their weight percentage concentrations 0.1%, 0.02%, 0.2% and 0.2%, respectively.

[0049] (2) According to the weight percentage, add 30 ml of sterile deionized water and 20 ml of glycerol into a beaker, and evenly sprinkle 1 g of Carbomer 940 under a magnetic stirrer; stir for about 6 hours until Carbomer 940 is fully swollen, and let it stand overnight to eliminate bubbles. Adjust the pH to about 6.5 with triethanolamine, and make up the above 50 ml mother solution to 100 ml to prepare a gel matrix.

[0050] (3) Finally, the mixed medicinal components in step (1) are added to the gel matrix in step (2) and stirred evenly to obtain a gynecological antibacterial gel.

[0051] Example 4: The Lactobacillus reuteri vesicle gynecological gel can effectively kill pathogens without inhibiting vaginal probiotics

[0052] 1. Detection of the bactericidal effect of α-mangostin on Staphylococcus aureus by broth dilution method

[0053] (1) Preparation of bacterial solution: Take Staphylococcus aureus (commercially available strain) in the logarithmic growth phase and use a UV spectrophotometer to detect OD = 0.1, which means the bacterial concentration is 1×10 8 CFU / mL, take 1 mL of bacterial solution, centrifuge at 5000 rpm for 5 min, discard the supernatant medium and resuspend with PBS, then dilute with PBS to 10 6 CFU / mL for later use;

[0054] (2) Drug preparation: prepare 1 ml of α-mangostin solution with a final concentration gradient of 100, 50, 25, 12.5, 6.25, 3.13, 1.56, 0.78, and 0.39 μg / ml;

[0055] (3) Adding drugs: Take 100 μL of each drug concentration and 100 μL of bacteria and add them to the same well of the 96-well plate, which is the experimental well. Add 100 μL of PBS and 100 μL of bacteria to the same well of the 96-well plate, which is the positive control well. The negative control well is set to 100 μL PBS + 100 μL blank culture medium. Place the 96-well plate in a 37°C incubator and incubate for 16 h. Then use an ELISA reader to read the absorbance As of each drug concentration at 600 nm. At the same time, read the negative control A 阴 , the positive control is read as A 阳;

[0056] Bacterial survival rate (%) = [( As-A 阴 ) / (A 阳 -A 阴 )]×100%;

[0057] like Figure 1 As shown, the experimental results prove that the α-mangostin in the Lactobacillus reuteri vesicle gynecological gel prepared by the present invention has a good bactericidal effect on Staphylococcus aureus within the above concentration range.

[0058] 2. Evaluation of the antibacterial effect of Lactobacillus reuteri vesicle gynecological gel loaded with natural active ingredients on Staphylococcus aureus by the inhibition zone method

[0059] (1) Sterilization of items. Before the test, the test samples were sterilized by high pressure wet heat and then dried.

[0060] (2) Bacterial suspension coating. Take 100 μL of the above 10 6 Use a spreading rod to spread the bacterial suspension evenly on the plate, cover the plate, and let it stand at room temperature for 5 minutes.

[0061] (3) Placement of antibacterial samples. Place three test samples and one control sample on a flat plate. Use sterile tweezers to take the samples and place them on the surface of the plate. The concentrations of α-mangostin in the three test samples are 6.25μg / ml, 12.5μg / ml, and 25μg / ml, respectively. The control sample does not contain α-mangostin. Both the test sample and the control sample do not contain other natural active ingredients. The distance between the centers of the samples is not less than 25mm, and the distance from the edge of the plate is not less than 15mm. After placing them, use sterile tweezers to gently press the samples to make them stick to the surface of the plate. Cover the plate and incubate at 37℃ for 16h~18h.

[0062] like Figure 2 As shown, the experimental results prove that the Lactobacillus reuteri vesicle gynecological gel prepared by the present invention has a good bactericidal effect on Staphylococcus aureus.

[0063] 3. Investigation of the effect of α-mangostin on Lactobacillus crispatus by broth microdilution method

[0064] (1) Preparation of bacterial solution: Take Lactobacillus crispatus in the logarithmic growth phase and use a UV spectrophotometer to detect OD = 0.1, which means the bacterial concentration is 1*10 8 CFU / mL, take 1 mL of bacterial solution, centrifuge at 5000 rpm for 5 min, discard the supernatant medium and resuspend with PBS, then dilute with PBS to 10 6 CFU / mL for later use;

[0065] (2) Drug preparation: prepare 1 ml of α-mangostin solution with a final concentration gradient of 200, 100, 50, 25, 12.5, 6.25, 3.125, and 1.56 μg / ml;

[0066] (3) Adding drugs: Take 100 μL of each concentration of drug and 100 μL of Lactobacillus crispatus and add them to the same well of the 96-well plate, which is the experimental well. Add 100 μL of PBS and 100 μL of Lactobacillus crispatus to the same well of the 96-well plate, which is the positive control well. The negative control well is set to 100 μL PBS + 100 μL blank culture medium. Place the 96-well plate in a 37 ℃ incubator and incubate for 16 h. Then use an ELISA reader to read the absorbance As of each drug concentration at 600 nm. At the same time, read the negative control A 阴 , the positive control is read as A 阳;

[0067] Bacterial survival rate (%) = [(A 阳 -As) / ( A 阳 -A 阴 )]×100%;

[0068] like Figure 3As shown, the experimental results prove that the α-mangostin in the Lactobacillus reuteri vesicle gynecological gel prepared by the present invention will not inhibit Lactobacillus crispatus at a therapeutic dose.

[0069] Example 5: Evaluation of the biocompatibility of α-mangostin on cells

[0070] The cytotoxicity of α-mangostin on human immortalized epidermal cells (Hacat cells) was tested by MTT assay. First, the Hacat cells in the cryopreserved tube were quickly shaken and dissolved in a 37°C water bath to avoid cell damage. Then, the cell culture medium was quickly transferred to a centrifuge tube containing 2 mL of complete culture medium and centrifuged at 1000 rpm / min for 5 min. The supernatant was discarded, and the centrifuged cells were resuspended in 1 mL of culture medium and quickly transferred to 5 mL of DMEM complete culture medium, placed in a 5% CO2 incubator at 37°C, and the well-cultured cells were digested and counted.

[0071] The calculation formula is as follows: number of cells / mL = number of cells in the four grids of the cell counting plate / 4×10 4 × dilution factor;

[0072] The counted Hacat cells were diluted to 8×10 4 cells / mL, 100 µL per well, cultured in a 96-well plate for 20 h. Subsequently, the pre-sterilized α-mangostin was prepared into a mixture of 1.56, 3.125, 6.25, 12.5, 25, 50, and 100 µg / mL using complete culture medium. 100 µL of each concentration was added to the Hacat cell solution cultured for 20 h, and co-cultured in a 5% CO2 incubator for 24 h. After adding 10 µL of MTT to the 96-well plate, the culture medium was poured out and 150 µL of dimethyl sulfoxide (DMSO) was added to each well. After thorough mixing, the absorbance at 490 nm was measured using a microplate reader. The cell viability was calculated according to the following formula: Cell viability (%) = [(A 阳 -As) / (A 阳 -A 阴 )]×100%.

[0073] like Figure 4 As shown, the experimental results prove that α-mangostin, the main component of the Lactobacillus reuteri vesicle gynecological gel prepared by the present invention, does not produce cytotoxic effects at a therapeutic dose.

[0074] Example 6: The Lactobacillus reuteri vesicle gynecological gel effectively kills Staphylococcus aureus and Candida albicans

[0075] (1) Modeling. Figure 5 As shown in the figure, the rat vaginitis animal model was established. Female Sprague‒Dawley (SD) rats (180-200 g) were intraperitoneally injected with 100 µL β-estradiol (5 mg / mL) once a day for 3 consecutive days before infection. Staphylococcus aureus (1×10 8 CFU / mL, 50 µL / d) were used to in situ infect the vagina of rats once a day for 7 consecutive days.

[0076] (2) Administration. After successful modeling, half of the modeled rats were treated with Lactobacillus reuteri vesicle gynecological gel loaded with natural active ingredients, while the control group (i.e. the remaining half of the modeled rats) did not receive any treatment. The drug was administered for seven consecutive days, and vaginal samples were taken with sterile cotton swabs and cultured on solid culture media.

[0077] (3) The establishment of the Candida albicans infected rat vaginitis model and the detection method after administration of the gel were the same as above.

[0078] like Figure 6 As shown, Figure 6 The left side is the control group, where vaginal sampling was performed using a sterile cotton swab and then cultured on a solid culture medium. Figure 6 The right side shows the situation of vaginal sampling with a sterile cotton swab and then culturing on a solid culture medium after the Staphylococcus aureus infection model group received continuous administration of the gel for seven days. The experimental results prove that the Lactobacillus reuteri vesicle gynecological gel of the present invention can effectively kill Staphylococcus aureus.

[0079] like Figure 7 As shown, Figure 7 The left side is the control group, where vaginal sampling was performed using a sterile cotton swab and then cultured on a solid culture medium. Figure 7 The right side shows the situation of vaginal sampling with sterile cotton swabs and then culturing on solid culture medium after the Candida albicans infection model group received continuous administration of the gel for seven days. The experimental results prove that the Lactobacillus reuteri vesicle gynecological gel of the present invention can effectively kill Candida albicans.

[0080] Example 7: The Lactobacillus reuteri vesicle gynecological gel effectively inhibits the inflammatory response of the vaginitis rat model induced by Staphylococcus aureus and Candida albicans

[0081] (1) Modeling. Female Sprague-Dawley (SD) rats (180–200 g) were intraperitoneally injected with 100 μL β-estradiol (5 mg / mL) once daily for 3 consecutive days before infection. Staphylococcus aureus (1×10 8 CFU / mL, 50 µL / d) and Candida albicans (1×10 8CFU / mL, 50 µL / d) were used to in situ infect the vagina of rats once a day for 7 consecutive days.

[0082] (2) Administration. After successful modeling, half of the modeled rats were treated with Lactobacillus reuteri vesicle gynecological gel loaded with natural active ingredients, while the control group (i.e., the remaining half of the modeled rats) did not receive any treatment. The drug was administered for seven consecutive days, and hematoxylin-eosin (H&E) staining was used to further evaluate the gynecological gel that reshapes the vaginal microenvironment and optimizes the flora structure, as well as the level of vaginal histological inflammation after application.

[0083] The experimental results are as follows Figure 8 , 9 As shown, H&E staining showed that inflammatory cell infiltration was visible in the control group, with more small round dark blue stained inflammatory cells and exfoliation of tissue epithelial mucosa. The gynecological gel group that reshaped the vaginal microenvironment and optimized the flora structure had fewer inflammatory cells and normal density of mucosal multilayer squamous epithelium, which was related to rapid bactericidal function and inflammation inhibition.

[0084] The above factual cases only represent the technical solutions of the present invention, rather than limiting the experiments. Although we have improved the experimental solutions, researchers in the same field can still make further improvements to the experimental solutions described above or make scientific equivalent replacements for the experimental links. These changes do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions claimed to be protected by the present invention.

Claims

1. A Lactobacillus reuteri vesicle gynecological gel for reshaping the vaginal microenvironment and optimizing the flora structure, characterized in that: The gynecological gel comprises the following components: 0.0025% of α-mangostin, 0.05% of asiatica glycoside, 0.05% of osthole, 0.01% of Lactobacillus reuteri vesicles, 0.1% of inulin, 1% of carbomer 940, 20% of glycerol, 0.1% of ethylparaben, triethanolamine to adjust pH to 6.5, and the balance is sterile deionized water; The preparation method of the Lactobacillus reuteri vesicle comprises the following steps: aseptically inoculating Lactobacillus reuteri into a culture medium for cultivation, centrifuging the culture fluid after cultivation, filtering the supernatant, concentrating the filtrate using an 80 kDa-120 kDa concentrator, and obtaining the vesicle by centrifugation.

2. The method for preparing the Lactobacillus reuteri vesicle gynecological gel for reshaping the vaginal microenvironment and optimizing the flora structure according to claim 1, characterized in that: The preparation method comprises the following steps: (1) First, α-mangostin and osthole are dissolved in an organic solvent respectively, and then sterile deionized water is added to dilute them into α-mangostin solution and osthole solution; then required amounts of asiatica glycoside, Lactobacillus reuteri vesicles, inulin and ethyl paraben are added to obtain a mixed active ingredient; the organic solvent is at least one of methanol, anhydrous ethanol, isopropanol or acetone; the volume ratio concentration of the organic solvent is 0.5% to 0.8%; The preparation method of the Lactobacillus reuteri vesicles comprises: inoculating Lactobacillus reuteri in a culture medium aseptically for cultivation, centrifuging the culture solution after cultivation, filtering the supernatant, concentrating the filtrate with an 80 kDa-120 kDa concentrator, and obtaining the vesicles by centrifugation; (2) Add carbomer 940 to sterile deionized water and glycerol while stirring; stir until carbomer 940 is fully swollen, and let stand overnight to eliminate bubbles; adjust the pH to 6-7 with triethanolamine, and add sterile deionized water to form a gel matrix; (3) Adding the mixed medicinal components into the gel matrix and stirring evenly to obtain the Lactobacillus reuteri vesicle gynecological gel.

3. Use of the Lactobacillus reuteri vesicle gynecological gel according to claim 1 in preparing a medicine for treating and improving gynecological vaginal inflammation.

4. The use according to claim 3, characterized in that: The Lactobacillus reuteri vesicle gynecological gel can effectively kill Staphylococcus aureus and Candida albicans.